IL6 and cancer: On the one hand, monotherapy with anti-inflammatory agents has been proved limited efficacy in cancer treatment, for example, monotherapy with agents targeting IL-6 only showed moderate activity against solid tumors in non-stratified patients (NCT00841191, NCT01531998).